Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
about
Aptamer-Mediated Targeted Delivery of Therapeutics: An UpdateEvolution of Complex Target SELEX to Identify Aptamers against Mammalian Cell-Surface AntigensTargeted Expression of miR-7 Operated by TTF-1 Promoter Inhibited the Growth of Human Lung Cancer through the NDUFA4 Pathway.RYK promotes the stemness of glioblastoma cells via the WNT/ β-catenin pathwayMicroRNA-targeted therapeutics for lung cancer treatment.Current and Prospective Protein Biomarkers of Lung Cancer.Current Advances in Aptamers for Cancer Diagnosis and Therapy.Molecular Elucidation of Disease Biomarkers at the Interface of Chemistry and Biology.Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection.Developing TRAIL/TRAIL death receptor-based cancer therapies.Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.miR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer CellsNucleic Acid Aptamers Targeting Epigenetic Regulators: An Innovative Therapeutic OptionStudy on Attenuating Angiogenesis and Epithelial-Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC23‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5
P2860
Q28066827-0A58EC9E-329E-42F7-B06A-08FB81BD32DCQ36266158-EB692AC1-2A6A-473A-BADB-A1D49F3B2C0EQ37718177-1CD504BD-483D-4F12-9645-E64DD672482BQ38721422-B568999D-66B5-4476-A097-9351EEBB94B7Q39014580-95AA53B5-3155-46A7-9854-56214FCD1981Q47130839-D2BFA21B-4593-464F-9F9D-B1FA6B4DCD29Q47561686-F84523BD-FC7A-4E25-9233-6C84C9101CBEQ48313209-1E74C91B-1F3E-4FAD-9C60-5CCEAE32FF69Q52589516-82A77DFE-6B8F-4EDB-B8EA-10281CF90FD0Q53701901-99580215-D965-43DC-BB3C-63FAB9DF4272Q55036897-4EE011A8-B9F5-459E-95B8-37F16BC3FCDCQ57128464-3B8FA8FC-FCE6-46E4-951A-767C96204BBAQ58549853-A0BDBF7B-FF82-444A-A005-FA6F223AC20BQ58704366-74AA3E24-C3D1-4AB9-87E6-36AD5FA4A473Q58757340-3F4EB257-6DEC-4E18-A531-7E96504C2DF8Q58779685-E1212DE9-5ACF-4DBB-864D-E3F2FD883322
P2860
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
@en
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
@nl
type
label
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
@en
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
@nl
prefLabel
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
@en
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
@nl
P2093
P2860
P356
P1476
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL
@en
P2093
Cristina Quintavalle
Elvira Donnarumma
Gerolama Condorelli
Giuseppina Roscigno
Margherita Iaboni
Paloma H Giangrande
Raffaela Fontanella
Valentina Russo
Vittorio de Franciscis
P2860
P356
10.1038/MTNA.2016.5
P577
2016-03-08T00:00:00Z